MAR 0.8 2005

Practitioner's Docket No. MPI00-344P1RRCEM

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	Meyers, Rachel E., et al		
Application No.:	09/945,326	Group No.:	1642
Filed:	August 31, 2001	Examiner:	Yu, Misook
For:	62112, A NOVEL HUMAN DEHYDROGENASE AND USES THEREOF		

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

AUTHORIZATION TO ACT IN A REPRESENTATIVE CAPACITY

Dear Sir:

The practitioner named below is authorized to conduct interviews and has the authority to bind the principal concerned. Furthermore, the practitioner is authorized to file correspondence in the above-identified application pursuant to 37 CFR 1.34:

Mario Cloutier
Limited Recognition Under 37 CFR §11.9(b)
Customer Number 30405 or
Millennium Pharmaceuticals, Inc.
40 Landsdowne Street
Cambridge, MA 02139

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10* I hereby certify that, on the date shown below, this correspondence is being: MAILING deposited with the United States Postal Service in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. 37 C.F.R. SECTION 1.8(a) 37 C.F.R. SECTION 1.10* with sufficient postage as first class mail. as "Express Mail Post Office to Addressee" Mailing Label No. TRANSMISSION transmitted by facsimile to the Patent and Trademark Office (703 × Signature Date: ___ March 8, 2005 Jonathan K. Hamm (type or print name of person certifying)

*WARNING: Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

(Page 1 of 2)

Practitioner's Docket No. MPI00-344P1RRCEM

This is not a Power of Attorney to the above-named practitioner.

Accordingly, the practitioner named above does not have authority to sign a request to change the correspondence address, a request for an express abandonment, a disclaimer, a power of attorney, or other document requiring the signature of the applicant, assignee of the entire interest or an attorney of record. If appropriate, a separate Power of Attorney to the above-named practitioner should be executed and filed in the United States Patent and Trademark Office.

Please continue to forward all written and telephonic communications to Jean M. Silveri at the address and telephone number listed below.

SIGNATURE of Practitioner of Record

	Respectfully submitted	
March 8, 2005	MILLENNIUM PHARM	

MILLENNIUM PHARMACEUTICALS, INC.

Ву _____

Jean M. Silveri Registration No. 39,030 20 Landsdowne Street Cambridge, MA 02139 Telephone – (617) 679-7336

Facsimile – (617) 551-8820

BEFORE THE OFFICE OF ENROLLMENT AND DISCIPLINE UNITED STATE PATENT AND TRADEMARK OFFICE

LIMITED RECOGNITION UNDER 37 CFR § 11.9(b)

Mario Cloutier is hereby given limited recognition under 37 CFR 11.9(b) as an employee of Millenium Pharmaceuticals to prepare and prosecute patent applications wherein Millenium Pharmaceuticals is the assignee of record of the entire interest in the invention claimed in the application. This limited recognition shall expire on the date appearing below, or when whichever of the following events first occurs prior to the date appearing below: (i) Mario Cloutier ceases to lawfully reside in the United States, (ii) Mario Cloutier's employment with Millenium Pharmaceuticals ceases or is terminated, or (iii) Mario Cloutier ceases to remain or reside in the United States on an H-1 visa.

This document constitutes proof of such recognition. The original of this document is on file in the Office of Enrollment and Discipline of the U.S. Patent and Trademark Office.

Expires: December 29, 2006

Harry I. Moatz

Director of Enrollment and Discipline